Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO-202 +/- Pembrolizumab in Advanced Solid Tumors
NCT05309187Phase 1Completed
- Sponsor
- Immune-Onc Therapeutics
- Start
- Apr 2022
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of IO-202 in solid tumor (3 arms), sponsored by Immune-Onc Therapeutics. Primary endpoints: Incidence of treatment-emergent and serious adverse events up to 2 years, Dose-limiting toxicities at 21 days and 1 more. Started Apr 2022; status: completed.
02
Drugs
IO-202
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05309187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309187.